Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLARION: Carfilzomib vs Bortezomib in Newly Diagnosed Multiple Myeloma
NCT01818752Phase 3Completed
- Sponsor
- Amgen
- Start
- Jul 2013
- Primary completion
- Jul 2016
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 30
01
Overview
A Phase 3 trial of carfilzomib in multiple myeloma (MM), sponsored by Amgen. Started Jul 2013; status: completed.
02
Drugs
carfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01818752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01818752.